{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:46:43Z","timestamp":1789771603725,"version":"4.0.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In this ongoing, open-label, phase 3b\/4 study, JN.1- and KP.2-encoding monovalent mRNA-1273 vaccines elicited robust neutralization of vaccine-matched variants (JN.1, KP.2) and cross-neutralized JN.1 subvariants circulating during the study (September 2024\u2013November 2024; KP.3.1.1, XEC, LP.8.1) in vaccinated adults, showing reduced cross-neutralization against all subvariants tested. No safety concerns were identified.<\/jats:p>","DOI":"10.1093\/ofid\/ofaf705","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:53:00Z","timestamp":1763470380000},"source":"Crossref","is-referenced-by-count":9,"title":["Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult Participants"],"prefix":"10.1093","volume":"12","author":[{"given":"Amparo L","family":"Figueroa","sequence":"first","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Girard","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darin K","family":"Edwards","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshan","family":"Nasir","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimball","family":"Johnson","sequence":"additional","affiliation":[{"name":"CenExel , Decatur, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hack","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cao","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"de Windt","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9215-3541","authenticated-orcid":false,"given":"Veronica","family":"Urdaneta","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2533-3982","authenticated-orcid":false,"given":"Frances","family":"Priddy","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituparna","family":"Das","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C","family":"Montefiori","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University Medical Center , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6254-1158","authenticated-orcid":false,"given":"Spyros","family":"Chalkias","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"2025120210562245400_ofaf705-B1","author":"World Health Organization"},{"key":"2025120210562245400_ofaf705-B2","author":"World Health Organization"},{"key":"2025120210562245400_ofaf705-B3","author":"World Health Organization"},{"key":"2025120210562245400_ofaf705-B4","author":"US Food and Drug Administration"},{"key":"2025120210562245400_ofaf705-B5","doi-asserted-by":"crossref","first-page":"126961","DOI":"10.1016\/j.vaccine.2025.126961","article-title":"mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice","volume":"54","author":"Lee","year":"2025","journal-title":"Vaccine"},{"key":"2025120210562245400_ofaf705-B6","author":"Centers for Disease Control and Prevention"},{"key":"2025120210562245400_ofaf705-B7","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1016\/S1473-3099(25)00015-5","article-title":"Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1","volume":"25","author":"Liu","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2025120210562245400_ofaf705-B8","doi-asserted-by":"crossref","first-page":"e736","DOI":"10.1016\/S1473-3099(24)00731-X","article-title":"Virological characteristics of the SARS-CoV-2 XEC variant","volume":"24","author":"Kaku","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025120210562245400_ofaf705-B9","author":"World Health Organization"},{"key":"2025120210562245400_ofaf705-B10","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/bioinformatics\/btab856","article-title":"CoV-Spectrum: analysis of globally shared SARS-CoV-2 data to identify and characterize new variants","volume":"38","author":"Chen","year":"2022","journal-title":"Bioinformatics"},{"key":"2025120210562245400_ofaf705-B11","author":"US Food and Drug Administration"},{"key":"2025120210562245400_ofaf705-B12","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1093\/infdis\/jiae067","article-title":"Interim report of the reactogenicity and immunogenicity of severe acute respiratory syndrome coronavirus 2 XBB-containing vaccines","volume":"230","author":"Chalkias","year":"2024","journal-title":"J Infect Dis"},{"key":"2025120210562245400_ofaf705-B13","author":"Wang"},{"key":"2025120210562245400_ofaf705-B14","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S1473-3099(25)00007-6","article-title":"The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant","volume":"25","author":"Suthar","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2025120210562245400_ofaf705-B15","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/S1473-3099(25)00058-1","article-title":"KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2","volume":"25","author":"Wang","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2025120210562245400_ofaf705-B16","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/S1473-3099(24)00688-1","article-title":"Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC","volume":"24","author":"Arora","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025120210562245400_ofaf705-B17","author":"Moderna"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf705\/65378272\/ofaf705.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/12\/ofaf705\/65378272\/ofaf705.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/12\/ofaf705\/65378272\/ofaf705.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:56:30Z","timestamp":1764690990000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf705\/8327161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf705","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,19]]},"article-number":"ofaf705"}}